Drugs for Heart Failure — MCQs
Drug used for euvolemic hyponatremia in patient with advanced congestive heart failure is?
Drug of choice for Digoxin induced Ventricular Tachycardia:
Which of the following drugs is primarily indicated for improving symptoms in congestive heart failure?
In acute left ventricular failure with pulmonary edema, which drug can be administered for immediate management?
Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?
Which of the following cardioselective betablockers has been shown to decrease mortality in patients with congestive heart failure?
A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?
Effects of beta blockers on the heart are all of the following except:
Digitalis is used in mitral stenosis to control the ventricular rate when the patient develops which condition?
Drugs for Heart Failure Indian Medical PG Practice Questions and MCQs
Question 1: Drug used for euvolemic hyponatremia in patient with advanced congestive heart failure is?
- A. Nesiritide
- B. Tolvaptan (Correct Answer)
- C. Metoprolol
- D. Hydrocortisone
Explanation: ***Tolvaptan*** - **Tolvaptan** is a selective **vasopressin V2-receptor antagonist** that promotes free water excretion (aquaresis) without significantly altering electrolyte balance, making it suitable for euvolemic hyponatremia [1]. - It works by blocking the action of **antidiuretic hormone (ADH)**, which is often elevated in patients with **congestive heart failure (CHF)** leading to water retention and hyponatremia [2]. *Nesiritide* - **Nesiritide** is a **recombinant human B-type natriuretic peptide (BNP)** that causes vasodilation and diuresis, but it is primarily used for acutely decompensated heart failure with signs of congestion, not specifically for euvolemic hyponatremia [1]. - While it can induce diuresis, its main role is to reduce **preload** and **afterload**, and it does not directly target the mechanism of euvolemic hyponatremia as effectively as an aquaretic agent [1]. *Metoprolol* - **Metoprolol** is a **beta-blocker** used to reduce heart rate and blood pressure, improving cardiac function in CHF patients. - It does not directly address **hyponatremia** and its mechanism of action is unrelated to water balance or sodium concentration. *Hydrocortisone* - **Hydrocortisone** is a **corticosteroid** used for conditions like adrenal insufficiency, inflammation, or allergic reactions. - It has no direct role in the management of **hyponatremia** or **congestive heart failure**.
Question 2: Drug of choice for Digoxin induced Ventricular Tachycardia:
- A. Diltiazem
- B. Propranolol
- C. Lignocaine (Correct Answer)
- D. Verapamil
Explanation: ***Lignocaine*** - **Lignocaine** (also known as lidocaine) is the drug of choice for digoxin-induced ventricular tachycardia due to its ability to suppress ventricular arrhythmias without further compromising cardiac contractility [1]. - It works by blocking **sodium channels** in the myocardium, reducing automaticity and stabilizing the cardiac membrane [1]. *Diltiazem* - **Diltiazem** is a calcium channel blocker primarily used for supraventricular tachycardias and angina [1]. - It is contraindicated in digoxin toxicity as it can worsen myocardial depression and AV nodal blockade [1]. *Propranolol* - **Propranolol** is a beta-blocker that can suppress some arrhythmias but is generally not the first-line treatment for digoxin-induced ventricular tachycardia [1]. - Beta-blockers can worsen **bradycardia** and **AV block** often seen in digoxin toxicity [1]. *Verapamil* - **Verapamil** is a calcium channel blocker similar to diltiazem and can exacerbate digoxin toxicity [1]. - It is known to increase serum **digoxin levels** and can worsen the underlying cardiotoxic effects.
Question 3: Which of the following drugs is primarily indicated for improving symptoms in congestive heart failure?
- A. Beta blockers
- B. Diuretics (Correct Answer)
- C. ACE inhibitor
- D. Aldosterone antagonist
Explanation: ***Diuretics*** - **Diuretics** are the PRIMARY agents for **symptom relief** in congestive heart failure. - They directly target fluid overload, providing immediate relief of symptoms like **dyspnea** and **edema**. - According to ACC/AHA guidelines, diuretics are recommended for **all CHF patients with fluid retention** for symptom management. - While they improve quality of life significantly, their main role is **symptom control** rather than mortality reduction. *ACE inhibitor* - **ACE inhibitors** are foundational in heart failure treatment, primarily improving **mortality** and preventing **cardiac remodeling**. - They reduce preload and afterload by inhibiting the **renin-angiotensin-aldosterone system**. - While they do improve symptoms secondarily through hemodynamic effects, their **primary indication** is mortality benefit and disease modification, not direct symptomatic relief. *Beta blockers* - While essential for **reducing mortality** and improving left ventricular function in heart failure, beta-blockers' primary aim is not direct symptomatic relief. - They can initially worsen symptoms in some patients due to a **negative inotropic effect**, although this usually improves over time. - Their main benefit is long-term mortality reduction and prevention of disease progression. *Aldosterone antagonist* - **Aldosterone antagonists** (e.g., spironolactone, eplerenone) are added to therapy to reduce **mortality** and hospitalizations in patients with reduced ejection fraction. - While they can help with fluid balance, their primary benefit is blocking the harmful effects of **aldosterone** on the heart and kidneys, not direct symptom improvement.
Question 4: In acute left ventricular failure with pulmonary edema, which drug can be administered for immediate management?
- A. Morphine (Correct Answer)
- B. Amlodipine
- C. Epinephrine
- D. Propranolol
Explanation: ***Morphine*** - **Morphine** is a key drug in the **acute management of left ventricular failure with pulmonary edema** - It provides **anxiolysis**, reduces **sympathetic drive**, and decreases **preload** through venodilation - Reduces **oxygen demand** and **work of breathing** in acute decompensation - Standard dose: **2-5 mg IV**, can be repeated as needed - Caution needed for **respiratory depression** and **hypotension**, but benefits outweigh risks in severe pulmonary edema *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that is **contraindicated in acute/decompensated heart failure** - Beta-blockers **reduce contractility** and can worsen acute cardiac output - While certain beta-blockers (carvedilol, metoprolol, bisoprolol) are used in **chronic stable heart failure**, propranolol is NOT a guideline-recommended agent for heart failure management - In acute settings, beta-blockers would precipitate or worsen decompensation *Amlodipine* - **Amlodipine** is a **dihydropyridine calcium channel blocker** used for hypertension and angina - **Not recommended in heart failure** as it can cause **negative inotropic effects** and peripheral edema - Does not provide mortality benefit and may worsen outcomes in LV dysfunction - Other vasodilators (nitrates, ACE inhibitors) are preferred *Epinephrine* - **Epinephrine** is a potent **catecholamine** with alpha and beta effects - Increases **heart rate**, **contractility**, and **systemic vascular resistance** - Would dramatically increase **myocardial oxygen demand** and **afterload** in LV failure - Reserved for **cardiac arrest** or **cardiogenic shock requiring inotropic support**, not routine LV failure management - Risk of **arrhythmias** and **ischemia**
Question 5: Which medication is commonly used in heart failure that also has aldosterone antagonistic properties?
- A. Carvedilol
- B. Spironolactone (Correct Answer)
- C. Abiraterone
- D. Sacubitril/Valsartan
Explanation: ***Spironolactone*** - **Spironolactone** is a **potassium-sparing diuretic** that acts as a **competitive antagonist of aldosterone** receptors, primarily in the collecting ducts of the kidneys. - This action leads to increased excretion of sodium and water, and retention of potassium, which is beneficial in **heart failure** by reducing fluid overload and mitigating the detrimental effects of aldosterone on cardiac remodeling. *Carvedilol* - **Carvedilol** is a **beta-blocker** with additional **alpha-1 blocking** properties, commonly used in heart failure to reduce heart rate, blood pressure, and myocardial oxygen demand. - It does not possess significant aldosterone antagonistic properties. *Sacubitril/Valsartan* - **Sacubitril/Valsartan** is an **angiotensin receptor-neprilysin inhibitor (ARNI)**. Valsartan is an **angiotensin receptor blocker (ARB)**, and sacubitril inhibits neprilysin, an enzyme that degrades natriuretic peptides. - While it modulates the **renin-angiotensin-aldosterone system (RAAS)** and is highly effective in heart failure, it does not directly antagonize aldosterone receptors. *Abiraterone* - **Abiraterone** is an **androgen-biosynthesis inhibitor** used in the treatment of **prostate cancer**. - Its primary mechanism involves inhibiting **CYP17**, an enzyme critical for androgen production, and it has no role in the management of heart failure or aldosterone antagonism.
Question 6: Which of the following cardioselective betablockers has been shown to decrease mortality in patients with congestive heart failure?
- A. Propranolol
- B. Bisoprolol (Correct Answer)
- C. Labetalol
- D. Pindolol
- E. Atenolol
Explanation: ***Bisoprolol*** - **Bisoprolol** is a highly cardioselective beta-1 blocker that has been extensively studied and proven to reduce mortality and morbidity in patients with **systolic congestive heart failure**. - It is one of the **"big three" beta-blockers** (along with **carvedilol** and **metoprolol succinate**) recommended for chronic heart failure management by major cardiology guidelines, supported by the **CIBIS-II trial**. *Atenolol* - **Atenolol** is a cardioselective beta-1 blocker commonly used for hypertension and angina. - Despite being cardioselective, it has **not been shown to reduce mortality** in patients with chronic heart failure and is generally **not recommended** for this indication due to lack of supportive clinical trial evidence. *Propranolol* - **Propranolol** is a non-selective beta-blocker that blocks both beta-1 and beta-2 receptors. - While effective for conditions like angina and arrhythmias, it is generally **not recommended** for chronic heart failure due to its non-selectivity and lack of evidence for mortality reduction in this specific patient population. *Labetalol* - **Labetalol** is an alpha- and beta-adrenergic blocker, often used in hypertensive emergencies and for managing hypertension in pregnancy. - It is **not indicated** for mortality reduction in chronic heart failure due to its different pharmacological profile and lack of clinical trial evidence supporting its use for this purpose. *Pindolol* - **Pindolol** is a non-selective beta-blocker with **intrinsic sympathomimetic activity (ISA)**, meaning it partially stimulates beta-receptors while blocking the effects of norepinephrine and epinephrine. - Beta-blockers with ISA are generally **contraindicated** in heart failure because their partial agonist activity can potentially worsen myocardial function, and they have not shown any mortality benefit.
Question 7: A diabetic patient with history of heart failure is prescribed pioglitazone. What complication may arise?
- A. Hepatotoxicity
- B. Pulmonary fibrosis
- C. Fluid retention (Correct Answer)
- D. Hypokalemia
Explanation: ***Fluid retention***- **Pioglitazone**, a thiazolidinedione (TZD), commonly causes **fluid retention** or edema [1].- This fluid retention can **exacerbate heart failure** symptoms and lead to cardiac decompensation, especially in patients with pre-existing heart conditions [1].*Hepatotoxicity*- While TZDs like pioglitazone have been associated with **liver dysfunction** in some cases, significant hepatotoxicity is rare and usually not the primary concern or most common serious side effect [1].- **Regular monitoring of liver enzymes** is recommended, but fluid retention leading to heart failure exacerbation is a more immediate and severe risk in this patient profile.*Pulmonary fibrosis*- **Pulmonary fibrosis** is not a known or common complication directly associated with pioglitazone use.- This complication is typically linked to other medications or systemic diseases.*Hypokalemia*- **Hypokalemia**, or low potassium levels, is generally not a direct side effect of pioglitazone.- Electrolyte imbalances associated with heart failure or diuretic use, rather than pioglitazone itself, are more likely causes of hypokalemia.
Question 8: Which of the following potassium-sparing diuretics was the first to be shown to reduce cardiac mortality in chronic heart failure patients?
- A. Spironolactone (Correct Answer)
- B. Amiloride
- C. Triamterene
- D. Eplerenone
Explanation: ***Spironolactone*** - **Spironolactone** was the first potassium-sparing diuretic shown to reduce **cardiac mortality** in patients with **chronic heart failure** in the **RALES trial** (Randomized Aldactone Evaluation Study). - Its beneficial effects in heart failure are primarily attributed to its **aldosterone receptor antagonist** properties, which counteract the harmful effects of aldosterone on the myocardium and vasculature, rather than just its diuretic effect. *Amiloride* - **Amiloride** is a potassium-sparing diuretic that works by directly inhibiting **epithelial sodium channels (ENaC)** in the collecting duct. - While it helps in potassium conservation, it has not been shown to significantly reduce cardiac mortality in chronic heart failure patients in clinical trials. *Triamterene* - **Triamterene** is another potassium-sparing diuretic that also directly inhibits **ENaC** in the collecting duct, similar to amiloride. - Like amiloride, it is used to prevent hypokalemia but lacks evidence for significant **cardiac mortality reduction** in chronic heart failure. *Eplerenone* - **Eplerenone** is a selective **aldosterone receptor antagonist**, similar to spironolactone, with fewer hormonal side effects. - While it has been shown to reduce **cardiac mortality** in chronic heart failure (e.g., in the EMPHASIS-HF trial), it was introduced later than spironolactone and was not the *first* to demonstrate this benefit.
Question 9: Effects of beta blockers on the heart are all of the following except:
- A. Decreases duration of systole (Correct Answer)
- B. Decrease in heart rate
- C. May decrease cardiac output initially.
- D. May precipitate heart failure in acute settings.
Explanation: ***Decreases duration of systole*** - Beta-blockers primarily prolong the **duration of systole** by extending the **ejection time** and slowing ventricular relaxation. - They also increase the **diastolic filling time** by reducing heart rate, impacting overall cardiac cycle duration. *Decrease in heart rate* - Beta-blockers block **beta-1 adrenergic receptors** in the heart, leading to a decrease in **sympathetic stimulation** and thus a reduced heart rate. - This effect is beneficial in conditions like **tachycardia** and **angina**, as it reduces myocardial oxygen demand. *May decrease cardiac output initially.* - By reducing heart rate and contractility, beta-blockers can initially decrease **cardiac output**, especially in patients with pre-existing **ventricular dysfunction**. - This effect is often transient, as chronic use can lead to beneficial remodeling and improved efficiency in some conditions. *May precipitate heart failure in acute settings.* - In patients with acutely decompensated heart failure or severe left ventricular dysfunction, beta-blockers can acutely worsen cardiac function due to their **negative inotropic effects**. - Therefore, beta-blockers are typically initiated cautiously at low doses in stable heart failure patients and are contraindicated in acute decompensation.
Question 10: Digitalis is used in mitral stenosis to control the ventricular rate when the patient develops which condition?
- A. Atrial fibrillation (Correct Answer)
- B. Right ventricular failure
- C. Acute pulmonary edema
- D. Myocarditis
Explanation: ***Atrial fibrillation*** - **Digitalis** (digoxin) is effective in **slowing the ventricular rate** in atrial fibrillation by increasing vagal tone and prolonging the refractory period of the AV node. - In **mitral stenosis**, an uncontrolled rapid ventricular rate due to atrial fibrillation can significantly reduce cardiac output and worsen symptoms. *Right ventricular failure* - While digitalis can improve contractility, its primary role in **RV failure** is not rate control; diuretics and afterload reduction are more commonly used. - A patient with isolated right ventricular failure due to mitral stenosis would not directly benefit from digitalis for rate control. *Acute pulmonary edema* - **Acute pulmonary edema** requires rapid diuresis, oxygen, and vasodilators to reduce preload and afterload. - Digitalis has a slower onset of action and is not the first-line treatment for acute pulmonary edema, especially if the cause is not related to a rapid ventricular rate. *Myocarditis* - **Myocarditis** is an inflammation of the heart muscle, and digitalis is generally avoided due to concerns about potentially worsening arrhythmias and myocardial damage in an inflamed heart. - Treatment for myocarditis focuses on supportive care and addressing the underlying cause, not rate control with digitalis unless specific arrhythmias develop.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free